Next, we tested the drug-induced apoptosis by standard chemotherapeutic agents and target therapies used in AML on silenced ME1 cells, and confirmed increased sensitivity of shME1 cells to Bcl-2 inhibitors (VEN) and ruxolitinib (Figure 6D–F). This evidence concerns the gene BCL2 and acute myeloid leukemia.